The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
Official Title: An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors
Study ID: NCT00272740
Brief Summary: The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors by estimating the Clinical Benefit Rate
Detailed Description:
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Research Site, Leuven, , Belgium
Research Site, Aarau, , Switzerland
Research Site, Bern, , Switzerland
Research Site, Genf, , Switzerland
Research Site, Lausanne, , Switzerland
Research Site, Mendrisio, , Switzerland
Research Site, Milano, , Switzerland
Research Site, St.Gallen, , Switzerland
Name: AstraZeneca Switzerland Medical Director, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR